Progyny, Inc. $PGNY Shares Purchased by Algert Global LLC

Algert Global LLC raised its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 35.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 595,805 shares of the company’s stock after buying an additional 154,930 shares during the period. Algert Global LLC owned about 0.69% of Progyny worth $12,822,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. lifted its position in shares of Progyny by 57.1% during the third quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock worth $15,156,000 after purchasing an additional 256,078 shares in the last quarter. Cresset Asset Management LLC grew its holdings in shares of Progyny by 715.3% in the second quarter. Cresset Asset Management LLC now owns 85,053 shares of the company’s stock valued at $1,871,000 after purchasing an additional 74,621 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Progyny in the second quarter valued at approximately $327,000. Fort Washington Investment Advisors Inc. OH increased its stake in Progyny by 33.1% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock worth $35,649,000 after buying an additional 412,395 shares during the period. Finally, Nomura Holdings Inc. purchased a new stake in Progyny during the 2nd quarter worth approximately $9,368,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on PGNY. Barclays started coverage on shares of Progyny in a research report on Monday, December 8th. They issued an “overweight” rating and a $29.00 price target for the company. Canaccord Genuity Group reduced their price objective on Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a research note on Wednesday, March 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Truist Financial lowered their target price on Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. Finally, BTIG Research cut their price target on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.45.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president owned 89,879 shares of the company’s stock, valued at $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 7,455 shares of company stock worth $129,515 over the last quarter. Insiders own 9.40% of the company’s stock.

Progyny Price Performance

PGNY stock opened at $17.50 on Monday. The business has a 50 day moving average price of $22.30 and a 200 day moving average price of $22.74. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 26.92, a PEG ratio of 1.17 and a beta of 1.01. Progyny, Inc. has a fifty-two week low of $16.75 and a fifty-two week high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The company had revenue of $318.40 million for the quarter, compared to analyst estimates of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, sell-side analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current year.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.